NCT00096044View on ClinicalTrials.gov

Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Leukemia
Interventions
BIOLOGICAL

rituximab

IV

DRUG

lenalidomide

Oral

Trial Locations (1)

14263-0001

Roswell Park Cancer Institute, Buffalo

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER